101 related articles for article (PubMed ID: 30075205)
1. Hypertonicity-imposed BCL-XL addiction primes colorectal cancer cells for death.
Heimer S; Knoll G; Steixner C; Calance DN; Trinh DT; Ehrenschwender M
Cancer Lett; 2018 Oct; 435():23-31. PubMed ID: 30075205
[TBL] [Abstract][Full Text] [Related]
2. Bax/Bak activation in the absence of Bid, Bim, Puma, and p53.
Zhang J; Huang K; O'Neill KL; Pang X; Luo X
Cell Death Dis; 2016 Jun; 7(6):e2266. PubMed ID: 27310874
[TBL] [Abstract][Full Text] [Related]
3. Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL.
Le Pen J; Maillet L; Sarosiek K; Vuillier C; Gautier F; Montessuit S; Martinou JC; Letaï A; Braun F; Juin PP
Cell Death Dis; 2016 Feb; 7(2):e2083. PubMed ID: 26844698
[TBL] [Abstract][Full Text] [Related]
4. Mcl-1 and Bcl-x
Hockings C; Alsop AE; Fennell SC; Lee EF; Fairlie WD; Dewson G; Kluck RM
Cell Death Differ; 2018 Mar; 25(4):721-734. PubMed ID: 29459767
[TBL] [Abstract][Full Text] [Related]
5. Bcl-xL stimulates Bax relocation to mitochondria and primes cells to ABT-737.
Renault TT; Teijido O; Missire F; Ganesan YT; Velours G; Arokium H; Beaumatin F; Llanos R; Athané A; Camougrand N; Priault M; Antonsson B; Dejean LM; Manon S
Int J Biochem Cell Biol; 2015 Jul; 64():136-46. PubMed ID: 25862283
[TBL] [Abstract][Full Text] [Related]
6. Hypertonicity counteracts MCL-1 and renders BCL-XL a synthetic lethal target in head and neck cancer.
Heimer S; Knoll G; Neubert P; Hammer KP; Wagner S; Bauer RJ; Jantsch J; Ehrenschwender M
FEBS J; 2021 Mar; 288(6):1822-1838. PubMed ID: 32710568
[TBL] [Abstract][Full Text] [Related]
7. Bcl-xL is an oncogenic driver in colorectal cancer.
Scherr AL; Gdynia G; Salou M; Radhakrishnan P; Duglova K; Heller A; Keim S; Kautz N; Jassowicz A; Elssner C; He YW; Jaeger D; Heikenwalder M; Schneider M; Weber A; Roth W; Schulze-Bergkamen H; Koehler BC
Cell Death Dis; 2016 Aug; 7(8):e2342. PubMed ID: 27537525
[TBL] [Abstract][Full Text] [Related]
8. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
9. BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy.
Ramesh P; Medema JP
Apoptosis; 2020 Jun; 25(5-6):305-320. PubMed ID: 32335811
[TBL] [Abstract][Full Text] [Related]
10. Bcl-xL controls a switch between cell death modes during mitotic arrest.
Bah N; Maillet L; Ryan J; Dubreil S; Gautier F; Letai A; Juin P; Barillé-Nion S
Cell Death Dis; 2014 Jun; 5(6):e1291. PubMed ID: 24922075
[TBL] [Abstract][Full Text] [Related]
11. NOXA-dependent contextual synthetic lethality of BCL-XL inhibition and "osmotic reprogramming" in colorectal cancer.
Knoll G; Riffelsberger P; Raats D; Kranenburg O; Ehrenschwender M
Cell Death Dis; 2020 Apr; 11(4):257. PubMed ID: 32312973
[TBL] [Abstract][Full Text] [Related]
12. The C-terminal helix of Bcl-x(L) mediates Bax retrotranslocation from the mitochondria.
Todt F; Cakir Z; Reichenbach F; Youle RJ; Edlich F
Cell Death Differ; 2013 Feb; 20(2):333-42. PubMed ID: 23079612
[TBL] [Abstract][Full Text] [Related]
13. Regulation of stress-induced nuclear protein redistribution: a new function of Bax and Bak uncoupled from Bcl-x(L).
Lindenboim L; Blacher E; Borner C; Stein R
Cell Death Differ; 2010 Feb; 17(2):346-59. PubMed ID: 19816507
[TBL] [Abstract][Full Text] [Related]
14. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Chen S; Dai Y; Harada H; Dent P; Grant S
Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
[TBL] [Abstract][Full Text] [Related]
15. The apoptosis inhibitor Bcl-xL controls breast cancer cell migration through mitochondria-dependent reactive oxygen species production.
Bessou M; Lopez J; Gadet R; Deygas M; Popgeorgiev N; Poncet D; Nougarède A; Billard P; Mikaelian I; Gonzalo P; Rimokh R; Gillet G
Oncogene; 2020 Apr; 39(15):3056-3074. PubMed ID: 32066881
[TBL] [Abstract][Full Text] [Related]
16. Hypertonicity-enforced BCL-2 addiction unleashes the cytotoxic potential of death receptors.
Sirtl S; Knoll G; Trinh DT; Lang I; Siegmund D; Gross S; Schuler-Thurner B; Neubert P; Jantsch J; Wajant H; Ehrenschwender M
Oncogene; 2018 Jul; 37(30):4122-4136. PubMed ID: 29706657
[TBL] [Abstract][Full Text] [Related]
17. BIM-mediated membrane insertion of the BAK pore domain is an essential requirement for apoptosis.
Weber K; Harper N; Schwabe J; Cohen GM
Cell Rep; 2013 Oct; 5(2):409-20. PubMed ID: 24120870
[TBL] [Abstract][Full Text] [Related]
18. A brewing understanding of the regulation of Bax function by Bcl-xL and Bcl-2.
Renault TT; Dejean LM; Manon S
Mech Ageing Dev; 2017 Jan; 161(Pt B):201-210. PubMed ID: 27112371
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells.
Lee SJ; Park HJ; Kim YH; Kim BY; Jin HS; Kim HJ; Han JH; Yim H; Jeong SY
Int J Mol Med; 2012 Aug; 30(2):443-50. PubMed ID: 22664653
[TBL] [Abstract][Full Text] [Related]
20. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M
Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
